Literature DB >> 25981385

Another Beginning for Cystic Fibrosis Therapy.

Pamela B Davis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25981385     DOI： 10.1056/NEJMe1504059

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies.

Authors:  Fatima Djouadi; Jean Bastin
Journal:  Cells       Date:  2019-03-28       Impact factor: 6.600

2.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

Review 3.  Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.

Authors:  W Zhang; X Zhang; Y H Zhang; D C Strokes; A P Naren
Journal:  Drugs Today (Barc)       Date:  2016-04       Impact factor: 2.245

4.  Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation.

Authors:  Eleonora Ferrari; Romina Monzani; Valeria R Villella; Speranza Esposito; Francesca Saluzzo; Federica Rossin; Manuela D'Eletto; Antonella Tosco; Fabiola De Gregorio; Valentina Izzo; Maria C Maiuri; Guido Kroemer; Valeria Raia; Luigi Maiuri
Journal:  Cell Death Dis       Date:  2017-01-12       Impact factor: 8.469

Review 5.  Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis.

Authors:  Speranza Esposito; Antonella Tosco; Valeria R Villella; Valeria Raia; Guido Kroemer; Luigi Maiuri
Journal:  Mol Cell Pediatr       Date:  2016-03-14

6.  A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.

Authors:  A Tosco; F De Gregorio; S Esposito; D De Stefano; I Sana; E Ferrari; A Sepe; L Salvadori; P Buonpensiero; A Di Pasqua; R Grassia; C A Leone; S Guido; G De Rosa; S Lusa; G Bona; G Stoll; M C Maiuri; A Mehta; G Kroemer; L Maiuri; V Raia
Journal:  Cell Death Differ       Date:  2016-04-01       Impact factor: 15.828

7.  Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database.

Authors:  Amelia Smith; Michael Barry
Journal:  BMJ Open       Date:  2020-11-14       Impact factor: 2.692
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.